Investigation of the Developmental, Nutritional and Hormonal Regulation of Ghrelin in Children and Young Adults With Prader-Willi Syndrome (PWS): Octreotide Intervention Sub-study
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Number of Participants With Decrease in Weight From Baseline to 6 Months
研究概览
简要总结
The purpose of this study is to investigate over a 6 month period the effect of octreotide therapy on food intake, sense of hunger, body weight, body composition, efficiency of burning calories, biomarkers of weight regulation and growth hormone markers in children and young Adults with Prader-Willi Syndrome(PWS).
详细描述
Obesity continues to be a prevalent health concern affecting every race of the American population. According to data from the World Health Organization, 54% of U.S. adults are overweight (body mass index (BMI) >25 kg/m2 ) and 22% are obese (BMI >30 kg/m2) (1). In addition, 25% of U.S. children are overweight or obese (1). Studies show that obese children are likely to become obese adults (2-5). Also, recent studies report significant years of life lost due to the impact of being an obese adult (6, 7). Thus, insights into the pathogenesis of childhood obesity and preventative measures are needed to combat the inevitable increase in worldwide incidence of obesity and its associated co-morbidities. Recent studies have identified a new gastroenteric hormone, ghrelin, as a long-term regulator of energy balance in humans (12). Ghrelin is a 28 amino acid acylated peptide which is an endogenous ligand of the growth hormone secretagogue receptor (GHS-R), a hypothalamic G-protein-coupled receptor (13). Enteroendocrine cells (X/A-like cells) of the stomach are the major site of ghrelin synthesis, although a minor proportion of ghrelin synthesis occurs in other sites such as the hypothalamus, pituitary, duodenum, jejunum and lung (14) (15, 16).
The hypothesis that hyperghrelinemia causes some of the features of PWS predicts that this disorder will be ameliorated (partially or completely) by lowering ghrelin levels. We have recently shown that the somatostatin agonist, octreotide, suppresses ghrelin levels in humans. If octreotide remains effective in longer term studies, the drug may become an adjuvant therapy, in addition to growth hormone, to control the insatiable appetite and morbid obesity seen in this condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 5 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of PWS confirmed by chromosome analysis
- •Ages 5 years to 21 years
- •BMI for age ≥ (greater-than or equal to)85th percentile
- •Written informed consent and assent obtained and willingness to comply with the study schedule and procedures
- •Free T4, Thyroid stimulating hormone (TSH) values in the normal range (either endogenous or with thyroxine replacement)
排除标准
- •Patients with any other clinically significant disease that would have an impact on body composition, including diabetes mellitus, chronic inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders
- •Concomitant use of an investigational drug or Octreotide in the past year
- •Use of steroids for longer than 7 days within the past 30 days
研究组 & 干预措施
Octreotide
Octreotide to be administered by subcutaneous injection three times daily while on study
干预措施: Octreotide (Drug)
Placebo
Placebo to be administered by subcutaneous injection three times daily while on study
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants With Decrease in Weight From Baseline to 6 Months
时间窗: 6 months
Number of participants who had a decrease in weight from baseline to 6 months of Octreotide or placebo therapy
Number of Participants With Decreased Skin-fold Measurements From Baseline to 6 Months
时间窗: 6 months
Number of participants with decreased skin-fold measurements from baseline to 6 months of Octreotide or Placebo therapy
Number of Participants With Decrease in Hunger and Food Intake
时间窗: 6 months
Measured by hunger and hyperphagia by questionnaires and parent-reported 72-hour food recall from baseline to 6 months. Multiple questionnaires consisting of a battery of free text answer questions and food diaries are combined in order to make a behavioral assessment of the participants food state of hunger and food intake. There is no defined scale for this assessment. Each participants responses and parent responses are combined.
Number of Participants With Improved Peptide YY (PYY) Regulation From Baseline to 6 Months
时间窗: 6 months
Number of participants with improved Peptide YY (PYY) regulation from baseline to 6 months of Octreotide or Placebo therapy
Number of Participants With Improved Adiponectin Regulation From Baseline to 6 Months
时间窗: 6 months
Number of participants with improved Adiponectin regulation from baseline to 6 months of Octreotide or Placebo therapy
Number of Participants With Decreased BMI Z-score From Baseline to 6 Months
时间窗: 6 months
Number of participants with decreased BMI z-score from baseline to 6 months of Octreotide or Placebo therapy
Number of Participants With Decrease in Fasting Total Ghrelin
时间窗: 6 months
Number of participants showing a decrease in Fasting total ghrelin from baseline to 6 months of treatment with Octreotide or placebo
Number of Participants With Improved Insulin Regulation From Baseline to 6 Months
时间窗: 6 months
Number of participants with improved Insulin regulation from baseline to 6 months of Octreotide or Placebo therapy. Insulin regulation was measured by immunochemiluminescent assay.
Number of Participants With Improved Leptin Regulation From Baseline to 6 Months
时间窗: 6 months
Number of participants with improved Leptin regulation from baseline to 6 months of Octreotide or Placebo therapy
次要结局
- Number of Participants With Decreased Body Composition From Baseline to 6 Months by BOD POD®(6 months)
- Number of Participants With Decreased Body-composition From Baseline to 6 Months by DEXA(6 months)